Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Platelet activating factor receptor antagonists improve the efficacy of experimental chemo- and radiotherapy

Texto completo
Autor(es):
da Silva Junior, Ildefonso Alves [1] ; de Sousa Andrade, Luciana Nogueira [2] ; Jancar, Sonia [1] ; Chammas, Roger [2]
Número total de Autores: 4
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Lab Imunofarmacol, Dept Imunol, Inst Ciencias Biomed, Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Hosp Clin HCFMUSP, ICESP, Lab Oncol Expt, Ctr Invest Translac Oncol, Fac Med, Sao Paulo, SP - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo de Revisão
Fonte: Clinics; v. 73, n. 1 2018.
Citações Web of Science: 1
Resumo

Platelet activating factor is a lipid mediator of inflammation, and in recent decades, it has emerged as an important factor in tumor outcomes. Platelet activating factor acts by specific binding to its receptor, which is present in both tumor cells and cells that infiltrate tumors. Pro-tumorigenic effects of platelet activating factor receptor in tumors includes promotion of tumor cell proliferation, production of survival signals, migration of vascular cells and formation of new vessels and stimulation of dendritic cells and macrophages suppressor phenotype. In experimental models, blocking of platelet activating factor receptor reduced tumor growth and increased animal survival. During chemotherapy and radiotherapy, tumor cells that survive treatment undergo accelerated proliferation, a phenomenon known as tumor cell repopulation. Work from our group and others showed that these treatments induce overproduction of platelet activating factor-like molecules and increase expression of its receptor in tumor cells. In this scenario, antagonists of platelet activating factor markedly reduced tumor repopulation. Here, we note that combining chemo- and radiotherapy with platelet activating factor antagonists could be a promising strategy for cancer treatment. (AU)

Processo FAPESP: 15/22814-5 - Câncer e coração: novos paradigmas de diagnóstico e tratamento
Beneficiário:Carlos Eduardo Negrão
Linha de fomento: Auxílio à Pesquisa - Temático
Processo FAPESP: 13/15719-0 - Associação de PRRs com receptores para mediadores lipídicos em macrófagos e células dendríticas
Beneficiário:Sônia Jancar
Linha de fomento: Auxílio à Pesquisa - Temático